PMID- 21812499
OWN - NLM
STAT- MEDLINE
DCOM- 20120126
LR  - 20240324
IS  - 1179-1969 (Electronic)
IS  - 1170-229X (Print)
IS  - 1170-229X (Linking)
VI  - 28
IP  - 8
DP  - 2011 Aug 1
TI  - Systemic therapies for metastatic renal cell carcinoma in older adults.
PG  - 635-49
LID - 10.2165/11592880-000000000-00000 [doi]
AB  - The introduction of targeted therapies has radically changed the treatment 
      paradigm for metastatic renal cell carcinoma (mRCC). However, multiple clinical 
      dilemmas have emerged. For instance, limited data are available to juxtapose the 
      safety and efficacy profile of targeted therapies between older and younger 
      adults. Herein, pivotal trials of vascular endothelial growth factor (VEGF)- and 
      mammalian target of rapamycin (mTOR)-directed therapies are assessed in the 
      context of their implications in treating older adults with mRCC. In general, 
      subset analyses from these pivotal studies suggest similar efficacy of targeted 
      therapies amongst older adults. Aging is accompanied by a multitude of 
      physiological changes, as well as an increased prevalence of co-morbidities. The 
      age-related toxicity profiles of targeted agents for mRCC are detailed to provide 
      a framework for the risks and benefits of these therapies in older adults. 
      Ultimately, tools such as the Comprehensive Geriatric Assessment (CGA) that 
      account for physiological (as opposed to chronological) age may prove useful in 
      the evaluation and treatment of older adults with mRCC.
FAU - Pal, Sumanta K
AU  - Pal SK
AD  - Division of Genitourinary Malignancies, Department of Medical Oncology 
      Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, 
      USA.
FAU - Vanderwalde, Ari
AU  - Vanderwalde A
FAU - Hurria, Arti
AU  - Hurria A
FAU - Figlin, Robert A
AU  - Figlin RA
LA  - eng
GR  - K12 CA001727/CA/NCI NIH HHS/United States
GR  - K12 2K12CA001727-16A1/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - New Zealand
TA  - Drugs Aging
JT  - Drugs & aging
JID - 9102074
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aging
MH  - Antineoplastic Agents/adverse effects/pharmacology/therapeutic use
MH  - Carcinoma, Renal Cell/complications/metabolism/*pathology/*therapy
MH  - Humans
MH  - Kidney Neoplasms/complications/metabolism/*pathology/*therapy
MH  - Molecular Targeted Therapy/adverse effects
MH  - Neoplasm Metastasis
PMC - PMC5333645
MID - NIHMS532119
EDAT- 2011/08/05 06:00
MHDA- 2012/01/27 06:00
PMCR- 2017/03/02
CRDT- 2011/08/05 06:00
PHST- 2011/08/05 06:00 [entrez]
PHST- 2011/08/05 06:00 [pubmed]
PHST- 2012/01/27 06:00 [medline]
PHST- 2017/03/02 00:00 [pmc-release]
AID - 4 [pii]
AID - 10.2165/11592880-000000000-00000 [doi]
PST - ppublish
SO  - Drugs Aging. 2011 Aug 1;28(8):635-49. doi: 10.2165/11592880-000000000-00000.